Loading...
Among 12,562 acute coronary syndrome (ACS) patients in the manufacturer-funded, multinational, randomized CURE trial, incidence of the composite endpoint of cardiovascular death, nonfatal MI, or stroke was significantly lower with aspirin plus clopidogrel (9.3%) than with aspirin alone (11.4%). To determine the optimal dose of aspirin in ACS patients, researchers conducted a substudy in which they divided the CURE subjects into 3 groups, based on the aspirin dose chosen by their physicians (≤100 mg/day, 101-199 mg/day, or ≥200 mg/day).
The 3 aspirin-dose groups had similar baseline characteristics, but the low dose was most common in Europe, the medium dose in Australia and New Zealand, and the high dose in North and South America. Consisten…